Max Planck Florida Institute scientist awarded Glaxo Smith Kline Neuroscience Discovery Award
June 10, 2015
The Federation of American Societies for Experimental Biology (FASEB) has honored Samuel M. Young, Jr. PhD, a Max Planck Research Group Leader at Max Planck Florida Institute for Neuroscience, with the Glaxo Smith Kline Neuroscience Discovery Award. The award will be presented at the Ion Regulation Conference at the end of June. As one of four recipients of the award, he will receive a small monetary award and will give a talk about his team’s recent research regarding the molecular mechanisms of voltage gated calcium channel regulation of the speed and efficacy of neurotransmitter release
His group’s goal is to uncover the molecular mechanisms of how synapses sustain neurotransmitter release to meet the functional demands of different neural circuits in which they are embedded within. A major focus of their research is determining the molecular mechanisms of how voltage gated calcium channels regulate neurotransmitter release. Results of their work may have wide ranging implications in the study of migraines, neuropathic pain, ataxias, and many other neurological disorders.
The purpose of the award is to honor early-career scientists to give them a platform to share their work at the FASEB Ion Channel Regulation meeting. FASEB is a 100-year-old organization joining 120,000 researchers worldwide. Their primary goal is to support biomedical research by holding educational meetings and disseminating research results.
Members of the BioFlorida network include emerging and established life science companies, universities, research institutions, hospitals, medical centers, incubators, economic development agencies, investors and service providers.